問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Taipei Venterans General Hospital Taoyuan Branch

Division of Hematology & Oncology

更新時間：2023-09-19

蕭慈慧
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

85Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蕭慈慧

Taipei Veterans General Hospital

Division of Thoracic Medicine

List

65Cases

2018-01-15 - 2029-06-30

Phase III

Active
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB(T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    KEYTRUDA

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting4Sites

2018-12-01 - 2019-11-07

Phase I

Active
A Phase I Multicenter Study of Immunotherapy in Combination with Chemoradiation in Patients with Advanced Solid Tumors (CLOVER)

  • Condition/Disease

    Carcinoma, Squamous Cell of Head and Neck Carcinoma, Non-Small-Cell Lung Small Cell Lung Carcinoma

  • Test Drug

    Durvalumab (MEDI4736) Tremelimumab

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting3Sites

2018-12-01 - 2027-12-31

Phase II/III

Active
A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL)

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Bevacizumab GDC-6036、Docetaxel Tencentriq、Carboplatin-GRY、Cisplatin NeoCorp、Gitrabin、Alimta、Entrectinib

Participate Sites
4Sites

Recruiting4Sites

楊政達
Linkou Chang Gung Medical Foundation

2018-08-01 - 2032-07-01

Phase III

Active
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS ≧ 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    RO5424802(Alectinib)、capsule、 150mg

Participate Sites
9Sites

Recruiting8Sites

2022-06-01 - 2027-07-30

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2023-03-01 - 2029-05-01

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2023-06-01 - 2025-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2024-01-01 - 2028-09-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2026-03-20 - 2028-01-27

Phase I

Active
A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants with Solid Tumours (IMFINZI-subQ)

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Imfinzi Imjudo Subcutaneous Durvalumab rHu (AZD4773)

Participate Sites
4Sites

Not yet recruiting4Sites

2017-05-01 - 2020-07-31

Phase III

Active
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)

  • Condition/Disease

    Non Small Cell Lung Cancer NSCLC

  • Test Drug

    Durvalumab / Tremelimumab

Participate Sites
11Sites

Recruiting2Sites

Terminated8Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

1 2 3 4 5 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB